Astellas Pharma Inc. (FRA:YPH)

Market Cap	20.95B +25.3%
Revenue (ttm)	11.56B +13.2%
Net Income	719.16M +128.1%
EPS	0.40 +128.3%
Shares Out	n/a
PE Ratio	29.12
Forward PE	n/a
Dividend	0.45 (3.96%)
Ex-Dividend Date	Sep 29, 2025

Volume	n/a
Average Volume	28
Open	11.36
Previous Close	11.43
Day's Range	11.36 - 11.36
52-Week Range	7.53 - 12.37
Beta	n/a
RSI	53.03
Earnings Date	Feb 4, 2026

About Astellas Pharma

Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms due to menopause; IZERVAY, a treatment for geographic atrophy secondary to age-related macular degeneration; EVRENZO, a treatment for anemia associated with ch...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 13,643
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: YPH

Financial Performance

In fiscal year 2025, Astellas Pharma's revenue was 1.91 trillion, an increase of 19.25% compared to the previous year's 1.60 trillion. Earnings were 50.75 billion, an increase of 197.72%.

Financial numbers in JPY